Results 91 to 100 of about 5,401 (177)

Vismodegib CRD from Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies

, 2017
Vismodegib CRD Calculation ...
Xiaoying Chen (268103), Paolo Vicini (2311993), Chandra Vage (706260), Erica L. Bradshaw-Pierce (15007500), Gang Li (34549), Mary E. Spilker (9917407), Ravi Visswanathan (7511996), Shinji Yamazaki (2039911), Judy Lucas (1480975)   +8 more
core   +1 more source

Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma

Dermatology Reports
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multiple studies demonstrated that the aberrant activation of Hedgehog signaling is a driver of BCC development, and its blockade represents a potential therapeutic ...
Luigi Scarpato, Marco Palla, Sabino Strippoli, Luca Tagliaferri, Luca Fania, Maristella Saponara, Anna Carbone, Francesco Spagnolo, Flavia Silvestri, Paolo Antonio Ascierto   +9 more
doaj   +1 more source

Die Behandlung des lokal fortgeschrittenen, inoperablen Basalzellkarzinoms - erste klinische Erfahrungen mit Vismodegib (Erivedge®)

, 2015
Einleitung: Basalzellkarzinome (BCCs) stellen den größten Anteil maligner Hauttumore dar. Die Aggressivität dieser semimalignen Tumore besteht in der lokalen Invasivität und Destruktion.Goldstandard ist die operative in sano Resektion des Tumors ...
Iro, H, Bohr, C, Traxdorf, M, Müller, S
core   +1 more source

Real-Life Experience with Sonidegib for Locally Advanced Basosquamous Carcinoma: A Case Series

Case Reports in Dermatology
Introduction: Basosquamous carcinoma is an uncommon subtype of basal cell carcinoma (BCC), characterized by aggressive local growth and metastatic potential, that mainly develops on the nose, perinasal area, and ears, representing 1.2–2.7% of all head ...
Enrico Bocchino, Simone Cappilli, Gerardo Palmisano, Andrea Paradisi, Alfredo Piccerillo, Alessandro Di Stefani, Ketty Peris   +6 more
doaj   +1 more source

Case Report Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face [PDF]

, 2020
Background. For large basal cell carcinomas (BCCs) of the head and neck, definitive surgery often requires extensive resection and reconstruction that may result in prolonged recovery and limited cosmesis.
Aidnag Z Diaz, Joseph I Clark, Marcel W Bekkenk, Fiori Alite, Richard W Borrowdale, Mehee Choi, Alec M Block   +6 more
core  

Vismodegib, a small-molecule inhibitor of the Hedgehog pathway for the treatment of advanced cancers

, 2010
Vismodegib (GDC-0449) is a small, orally administrable molecule, belonging to the 2-arylpyridine class, which was discovered by Genentech Inc under a collaboration with Curis Inc.
FERRETTI, ELISABETTA, DE SMAELE, Enrico, GULINO, Alberto   +2 more
core  

Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.

PLoS ONE
Basal cell carcinoma (BCC) is highly curable by surgical excision or radiation. In rare cases, BCC can be locally destructive or difficult to surgically remove. Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50-60% response rate.
Shivani Patel, Heather Armbruster, Gretchen Pardo, Brianna Archambeau, Na Hyun Kim, Joanne Jeter, Richard Wu, Kari Kendra, Carlo M Contreras, Natalie Spaccarelli, Brittany Dulmage, Llana Pootrakul, David R Carr, Claire Verschraegen   +13 more
doaj   +1 more source

PHARMACEUTICAL COMPOSITION OF VISMODEGIB CAPSULES 150 mg

A stabilized pharmaceutical composition comprising Vismodegib or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said composition simultaneously achieves desired dissolution profile, stability ...
Anonymous,
core   +2 more sources

Immunohistochemical markers of advanced basal cell carcinoma: CD56 is associated with a lack of response to vismodegib

, 2016
International audienceVismodegib is an effective treatment for advanced basal cell carcinoma (BCC), but primary resistance to vismodegib remains to be elucidated.
Knol, Ac., Castillo, Jm, Saint-Jean, M., Nguyen, J. M., Dréno, Brigitte, Khammari, Amir   +5 more
core   +1 more source

Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances

Journal of Ophthalmology
Purpose. Basal cell carcinoma (BCC) is the most frequent malignant periocular tumor. It is associated with exposure to ultraviolet radiation, and its incidence is gradually increasing.
Alvaro Bengoa-González, Enrique Mencía-Gutiérrez, María Garrido, Elena Salvador, María-Dolores Lago-Llinás   +4 more
doaj   +1 more source